Monocytes can develop into dendritic cells (DCs) that migrate to lymph nodes (LNs) and present antigens to T cells. However, we find that this differentiation is blocked when monocytes accumulate subcutaneously in response to bacteria or lipopolysaccharide (LPS). The inhibition of DC differentiation is mediated by the bacteria and in conjunction with inflammatory cells recruited at the site of injection. Inhibition of migratory DC development was reversed in Toll-like receptor (TLR)4-mutated mice when LPS, but not whole bacteria, was injected, suggesting that TLR4 is one but not the only mediator of the inhibition. The block imposed by bacteria was partly relieved by the absence of interleukin (IL)-12 p40, but not by individual absence of several cytokines involved in DC differentiation or in inflammation, i.e., IL-6, IL-10, IL-12 p35, and interferon γ. Consistent with the inability of monocytes to yield migrating DCs, and the finding that other DCs had limited access to particulate or bacterial antigens, these antigens were weakly presented to T cells in the draining LN. These results illustrate that bacteria-associated signals can have a negative regulatory role on adaptive immunity and that local innate responses for containment of infectious bacteria can at least initially supersede development of adaptive responses.
Skip Nav Destination
Article navigation
20 October 2003
Article|
October 20 2003
Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo
Gianluca Rotta,
Gianluca Rotta
1Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
Search for other works by this author on:
Emmerson W. Edwards,
Emmerson W. Edwards
2Carl C. Icahn Center for Gene Therapy and Molecular Medicine, Mt. Sinai School of Medicine, New York, NY 10029
Search for other works by this author on:
Sabina Sangaletti,
Sabina Sangaletti
3Immunotherapy and Gene Therapy Unit, Istituto Nazionale dei Tumori, 20133 Milan, Italy
Search for other works by this author on:
Clare Bennett,
Clare Bennett
4Department of Cell Biology and Histology, Academic Medical Centre, 1105 AZ Amsterdam, Netherlands
Search for other works by this author on:
Simona Ronzoni,
Simona Ronzoni
1Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
Search for other works by this author on:
Mario P. Colombo,
Mario P. Colombo
3Immunotherapy and Gene Therapy Unit, Istituto Nazionale dei Tumori, 20133 Milan, Italy
Search for other works by this author on:
Ralph M. Steinman,
Ralph M. Steinman
5Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021
Search for other works by this author on:
Gwendalyn J. Randolph,
Gwendalyn J. Randolph
2Carl C. Icahn Center for Gene Therapy and Molecular Medicine, Mt. Sinai School of Medicine, New York, NY 10029
Search for other works by this author on:
Maria Rescigno
Maria Rescigno
1Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
Search for other works by this author on:
Gianluca Rotta
1Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
Emmerson W. Edwards
2Carl C. Icahn Center for Gene Therapy and Molecular Medicine, Mt. Sinai School of Medicine, New York, NY 10029
Sabina Sangaletti
3Immunotherapy and Gene Therapy Unit, Istituto Nazionale dei Tumori, 20133 Milan, Italy
Clare Bennett
4Department of Cell Biology and Histology, Academic Medical Centre, 1105 AZ Amsterdam, Netherlands
Simona Ronzoni
1Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
Mario P. Colombo
3Immunotherapy and Gene Therapy Unit, Istituto Nazionale dei Tumori, 20133 Milan, Italy
Ralph M. Steinman
5Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021
Gwendalyn J. Randolph
2Carl C. Icahn Center for Gene Therapy and Molecular Medicine, Mt. Sinai School of Medicine, New York, NY 10029
Maria Rescigno
1Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
Address correspondence to Maria Rescigno, Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti, 435, 20141 Milano, Italy. Phone: 39-02-57489866; Fax: 39-02-57489851; email: [email protected]
The online version of this article contains supplemental material.
Abbreviations used in this paper: CFSE, carboxyl-fluorescein-succinimidyl ester; DLN, draining LN; GFP, green fluorescent protein; i.d., intradermal(ly); LB, lurian broth; LC, Langerhans cell; TLR, Toll-like receptor.
Received:
March 03 2003
Revision Received:
September 09 2003
Accepted:
September 12 2003
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2003
J Exp Med (2003) 198 (8): 1253–1263.
Article history
Received:
March 03 2003
Revision Received:
September 09 2003
Accepted:
September 12 2003
Citation
Gianluca Rotta, Emmerson W. Edwards, Sabina Sangaletti, Clare Bennett, Simona Ronzoni, Mario P. Colombo, Ralph M. Steinman, Gwendalyn J. Randolph, Maria Rescigno; Lipopolysaccharide or Whole Bacteria Block the Conversion of Inflammatory Monocytes into Dendritic Cells In Vivo . J Exp Med 20 October 2003; 198 (8): 1253–1263. doi: https://doi.org/10.1084/jem.20030335
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement